Profile data is unavailable for this security.
About the company
Jazz Pharmaceuticals PLC is a biotechnology company. The Company is engaged in developing medicines for people with serious diseases. The Company’s lead marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium) AND Vyxeos (daunorubicin and cytarabine) liposome for injection. The Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution product is for the treatment of cataplexy or excessive daytime sleepiness (EDS), in patients with narcolepsy seven years of age and older. The Xyrem (sodium oxybate) oral solution product is for the treatment of cataplexy or EDS in patients with narcolepsy seven years of age and older. The Defitelio (defibrotide sodium) product is for the treatment of hepatic veno-occlusive disease (VOD).
- Revenue in USD (TTM)3.83bn
- Net income in USD414.83m
- Incorporated2005
- Employees2.80k
- LocationJazz Pharmaceuticals PLCFifth FlWaterloo Exchange, Waterloo RoadDUBLIN 4IrelandIRL
- Phone+353 16347800
- Fax+353 16347850
- Websitehttps://www.jazzpharma.com/
More ▼
Mergers & acquisitions
| Acquired company | JAZZ:NSQ since announced | Transaction value |
|---|---|---|
| Redx Pharma PLC-KRAS Inhibitor Program | -12.73% | -- |
Data delayed at least 15 minutes, as of Apr 22 2024 21:00 BST.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Blueprint Medicines Corp | 249.38m | -506.98m | 5.32bn | 655.00 | -- | 40.66 | -- | 21.32 | -8.37 | -8.37 | 4.12 | 2.14 | 0.2079 | 0.3354 | 6.23 | 380,732.80 | -42.26 | -29.92 | -50.67 | -34.06 | 96.58 | -- | -203.30 | -116.65 | 3.66 | -25.88 | 0.6465 | -- | 22.22 | 41.14 | 9.06 | -- | 4.85 | -- |
| Apellis Pharmaceuticals Inc | 396.59m | -528.63m | 5.73bn | 702.00 | -- | 29.21 | -- | 14.45 | -4.48 | -4.48 | 3.34 | 1.63 | 0.5121 | 0.5042 | 3.70 | 564,944.40 | -68.26 | -73.88 | -93.25 | -90.03 | 85.25 | -- | -133.29 | -326.49 | 2.50 | -59.78 | 0.6775 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Revolution Medicines Inc | 11.58m | -436.37m | 5.75bn | 378.00 | -- | 3.15 | -- | 496.63 | -3.77 | -3.77 | 0.1024 | 11.09 | 0.0081 | -- | 3.91 | 30,634.92 | -30.37 | -29.76 | -32.71 | -32.59 | -- | -- | -3,768.28 | -606.93 | -- | -- | 0.00 | -- | -67.27 | -10.50 | -75.46 | -- | 38.82 | -- |
| Ionis Pharmaceuticals Inc | 787.65m | -366.29m | 5.93bn | 927.00 | -- | 15.18 | -- | 7.53 | -2.56 | -2.56 | 5.50 | 2.68 | 0.2852 | 0.362 | 12.77 | 849,673.10 | -13.26 | -6.30 | -15.38 | -7.44 | 98.84 | 98.75 | -46.50 | -21.23 | 5.83 | -- | 0.7671 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Elanco Animal Health Inc | 4.42bn | -1.23bn | 6.38bn | 9.30k | -- | 1.03 | -- | 1.45 | -2.50 | -2.50 | 8.96 | 12.63 | 0.2959 | 1.18 | 5.39 | 474,946.30 | -8.25 | -3.27 | -9.15 | -3.65 | 56.28 | 54.28 | -27.87 | -11.53 | 1.35 | 1.18 | 0.4813 | -- | 0.136 | 7.57 | -1,478.21 | -- | 2.74 | -- |
| Vaxcyte Inc | 0.00 | -402.27m | 6.59bn | 254.00 | -- | 4.68 | -- | -- | -4.07 | -4.07 | 0.00 | 13.01 | 0.00 | -- | -- | 0.00 | -33.33 | -34.22 | -36.11 | -37.21 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -80.00 | -- | 107.28 | -- |
| Exelixis Inc | 1.83bn | 207.77m | 6.83bn | 1.31k | 34.80 | 3.01 | 29.24 | 3.73 | 0.6472 | 0.6472 | 5.69 | 7.48 | 0.6087 | 2.87 | 8.09 | 1,397,105.00 | 6.91 | 8.86 | 7.85 | 9.91 | 96.04 | 96.30 | 11.35 | 15.43 | 3.30 | -- | 0.00 | 0.00 | 13.60 | 16.47 | 13.98 | -21.34 | 3.98 | -- |
| Jazz Pharmaceuticals PLC | 3.83bn | 414.83m | 6.85bn | 2.80k | 17.97 | 1.83 | 6.49 | 1.79 | 6.12 | 6.12 | 53.20 | 60.03 | 0.345 | 0.6645 | 5.65 | 1,369,359.00 | 3.76 | 1.48 | 4.23 | 1.62 | 88.64 | 88.79 | 10.90 | 4.26 | 1.85 | 2.06 | 0.6048 | 0.00 | 4.78 | 15.19 | 285.14 | -1.49 | -20.04 | -- |
| Viking Therapeutics Inc | 0.00 | -85.90m | 6.99bn | 27.00 | -- | 18.22 | -- | -- | -0.9153 | -0.9153 | 0.00 | 3.48 | 0.00 | -- | -- | 0.00 | -31.99 | -21.91 | -34.64 | -23.04 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -24.73 | -- | -- | -- |
| Intra-Cellular Therapies Inc | 464.37m | -139.67m | 7.01bn | 610.00 | -- | 11.79 | -- | 15.09 | -1.46 | -1.46 | 4.84 | 6.14 | 0.6262 | 1.90 | 4.91 | 761,262.30 | -18.84 | -38.27 | -21.89 | -42.77 | 92.73 | -- | -30.08 | -128.42 | 5.31 | -- | 0.00 | -- | 85.51 | -- | 45.49 | -- | -7.22 | -- |
| Cytokinetics, Inc. | 7.53m | -526.24m | 7.06bn | 423.00 | -- | -- | -- | 938.13 | -5.45 | -5.45 | 0.078 | -3.80 | 0.0082 | -- | 10.53 | 17,801.42 | -57.23 | -43.14 | -63.72 | -47.22 | -- | -- | -6,988.63 | -540.47 | -- | -16.52 | 2.66 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
| Bellring Brands Inc | 1.73bn | 165.20m | 7.07bn | 420.00 | 43.61 | -- | 33.54 | 4.08 | 1.24 | 1.24 | 12.99 | -2.19 | 2.39 | 5.89 | 9.62 | 4,129,762.00 | 22.78 | 18.89 | 29.01 | -- | 32.08 | 32.44 | 9.52 | 10.10 | 1.71 | 4.39 | 1.53 | 0.00 | 21.53 | 15.03 | 101.09 | 13.80 | -18.48 | -- |
| Cerevel Therapeutics Holdings Inc | 0.00 | -432.84m | 7.66bn | 334.00 | -- | 11.36 | -- | -- | -2.66 | -2.66 | 0.00 | 3.71 | 0.00 | -- | -- | 0.00 | -38.29 | -- | -41.29 | -- | -- | -- | -- | -- | -- | -- | 0.3337 | -- | -- | -- | -23.14 | -- | -- | -- |
| Legend Biotech Corp (ADR) | 285.14m | -518.25m | 8.40bn | 1.80k | -- | 6.71 | -- | 29.47 | -2.95 | -2.95 | 1.62 | 6.88 | 0.1794 | 9.68 | 5.70 | 158,412.80 | -32.60 | -37.71 | -38.89 | -47.19 | 49.42 | -- | -181.75 | -286.51 | 6.83 | -24.23 | 0.208 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
Data as of Apr 22 2024. Currency figures normalised to Jazz Pharmaceuticals PLC's reporting currency: US Dollar USD
38.00%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2023 | 6.21m | 9.96% |
| BlackRock Fund Advisorsas of 31 Dec 2023 | 5.58m | 8.95% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 2.42m | 3.88% |
| LSV Asset Managementas of 31 Dec 2023 | 2.34m | 3.76% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 1.29m | 2.06% |
| Wellington Management Co. LLPas of 31 Dec 2023 | 1.28m | 2.05% |
| Polaris Capital Management LLCas of 31 Dec 2023 | 1.27m | 2.03% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.23m | 1.98% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.05m | 1.68% |
| Pacer Advisors, Inc.as of 31 Dec 2023 | 1.02m | 1.64% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
